Get Adobe Flash player
Pituitary Disorders 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 70 Melmed S, Medical progress: Acromegaly, N Engl J Med, 2006;355(24):2558–73. Neggers SJ, Biermasz NR, van der Lely AJ, What is active acromegaly and which parameters do we have?, Clin Endocrinol (Oxf), 2012;76(5):609–14. Krentz AJ, Boyle PJ, Macdonald LM, Schade DS, Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations, Metabolism, 1994;43(1):24–31. Presti ME, Burton FR, Niehoff ML, et al., Effect of octreotide on stimulated insulin release from pancreatic tissue slices, Pancreas, 1998;16(2):141–7. Leung KC, Doyle N, Ballesteros M, et al., Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation, J Clin Endocrinol Metab, 2000;85(12):4712–20. Neggers SJ, Kopchick JJ, Jorgensen JO, van der Lely AJ, Hypothesis: Extra-hepatic acromegaly: a new paradigm?, Eur J Endocrinol, 2011;164(1):11–16. Rabinowitz D, Merimee TJ, Burgess JA, Riggs L, Growth hormone and insulin release after arginine: indifference to hyperglycemia and epinephrine, J Clin Endocrinol Metab, 1966;26(10):1170–72. List EO, Palmer AJ, Berryman DE, et al., Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes, Diabetologia, 2009;52(8):1647–55. Berryman DE, List EO, Coschigano KT, et al., Comparing adiposity profiles in three mouse models with altered GH signaling, Growth Horm IGF Res, 2004;14(4):309–18. Berryman DE, List EO, Kohn DT, et al., Effect of growth hormone on susceptibility to diet-induced obesity, Endocrinology, 2006;147(6):2801–8. Berryman DE, List EO, Palmer AJ, et al., Two-year body composition analyses of long-lived GHR null mice, J Gerontol A Biol Sci Med Sci, 2010;65(1):31–40. Yakar S, Liu JL, Stannard B, et al., Normal growth and development in the absence of hepatic insulin-like growth factor I, Proc Natl Acad Sci U S A, 1999;96(13):7324–9. Yang CW, Striker GE, Chen WY, et al., Differential expression of glomerular extracellular matrix and growth factor mRNA in rapid and slowly progressive glomerulosclerosis: studies in mice transgenic for native or mutated growth hormone, Lab Invest, 1997;76(4):467–76. Yang CW, Striker LJ, Kopchick JJ, et al., Glomerulosclerosis in mice transgenic for native or mutated bovine growth hormone gene, Kidney Int Suppl, 1993;39:S90–94. Yang CW, Striker LJ, Pesce C, et al., Glomerulosclerosis and body growth are mediated by different portions of bovine growth hormone. Studies in transgenic mice, Lab Invest, 1993;68(1):62–70. Chen NY, Chen WY, Kopchick JJ, A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin, Endocrinology, 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 1996;137(11):5163–5. Esposito C, Liu ZH, Striker GE, et al., Inhibition of diabetic nephropathy by a GH antagonist: a molecular analysis, Kidney Int, 1996;50(2):506–14. Flyvbjerg A, Bennett WF, Rasch R, et al., Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice, Diabetes, 1999;48(2):377–82. Frystyk J, Delhanty PJ, Skjaerbaek C, Baxter RC, Changes in the circulating IGF system during short-term fasting and refeeding in rats, Am J Physiol, 1999;277(2 Pt 1):E245–52. Ogilvy-Stuart AL, Hands SJ, Adcock CJ, et al., Insulin, insulin- like growth factor I (IGF-I), IGF-binding protein-1, growth hormone, and feeding in the newborn, J Clin Endocrinol Metab, 1998;83(10):3550–57. Shishko PI, Dreval AV, Abugova IA, et al., Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion, Diabetes Res Clin Pract, 1994;25(1):1–12. Wurzburger MI, Prelevic GM, Sonksen PH, et al., Effect of recombinant human growth hormone treatment on insulin- like growth factor (IGF-I) levels in insulin-dependent diabetic patients, Acta Diabetol, 1995;32(2):131–4. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW, Pituitary tumours: the sst/D2 receptors as molecular targets, Mol Cell Endocrinol, 2010;326(1–2):89–98. Castinetti F, Saveanu A, Morange I, Brue T, Lanreotide for the treatment of acromegaly, Adv Ther, 2009;26(6):600–12. Freda PU, Katznelson L, van der Lely AJ, et al., Long-acting somatostatin analog therapy of acromegaly: a meta-analysis, J Clin Endocrinol Metab, 2005;90(8):4465–73. Melmed S, Sternberg R, Cook D, et al., A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly, J Clin Endocrinol Metab, 2005;90(7):4405–10. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ, Octreotide, N Engl J Med, 1996;334(4):246–54. Laursen T, Moller J, Fisker S, et al., Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients, Growth Horm IGF Res, 1999;9(6):451–7. Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ, Pituitary- independent effect of octreotide on IGF1 generation, Eur J Endocrinol, 2009;160(4):543–8. Rubeck KZ, Madsen M, Andreasen CM, et al., Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery, Eur J Endocrinol, 2010;163(5):717–26. Bonapart IE, van Domburg R, ten Have SM, et al., The ‘bio- assay’ quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations, Eur J Endocrinol, 2005;152(2):217–24. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. Neggers SJ, van Aken MO, de Herder WW, et al., Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant, J Clin Endocrinol Metab, 2008;93(10):3853–9. Chen WY, Wight DC, Mehta BV, et al., Glycine 119 of bovine growth hormone is critical for growth-promoting activity, Mol Endocrinol, 1991;5(12):1845–52. Chen XZ, Shafer AW, Yun JS, et al., Conversion of bovine growth hormone cysteine residues to serine affects secretion by cultured cells and growth rates in transgenic mice, Mol Endocrinol, 1992;6(4):598–606. Dattani MT, Hindmarsh PC, Brook CG, et al., G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells, J Biol Chem, 1995;270(16):9222–6. van der Lely AJ, Hutson RK, Trainer PJ, et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, Lancet, 2001;358(9295):1754–9. Moller L, Norrelund H, Jessen N, et al., Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects, J Clin Endocrinol Metab, 2009;94(11):4524–32. Giustina A, Chanson P, Bronstein MD, et al., A consensus on criteria for cure of acromegaly, J Clin Endocrinol Metab, 2010;95(7):3141–8. Feenstra J, de Herder WW, ten Have SM, et al., Combined therapy with SMSA and weekly pegvisomant in active acromegaly, Lancet, 2005;365(9471):1644–6. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al., Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist, J Clin Endocrinol Metab, 2005;90(10):5627–31. Webb SM, Badia X, Surinach NL, Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study, Eur J Endocrinol, 2006;155(2):269–77. Badia X, Webb SM, Prieto L, Lara N, Acromegaly quality of life questionnaire (AcroQoL), Health Qual Life Outcomes, 2004;2:13. Webb SM, Prieto L, Badia X, et al., Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties, Clin Endocrinol (Oxf), 2002;57(2):251–8. Sievers C, Brubach K, Saller B, et al., Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS), Clin Endocrinol (Oxf), 2010;73(1):89–94. Madsen M, Poulsen PL, Orskov H, et al., Cotreatment with pegvisomant and a somatostatin analog (SA) in SA- responsive acromegalic patients, J Clin Endocrinol Metab, 2011;96(8):2405–13. Neggers SJ, van der Lely AJ, Somatostatin analog and pegvisomant combination therapy for acromegaly, Nat Rev Endocrinol, 2009;5(10):546–52. US E ndocrinology